Who are we
Biological medicines have revolutionized the treatment of many diseases.1,2 However, their high cost places a significant burden on healthcare systems and can hinder patient access.1,3
When the patent for a biological ‘reference’ medicine expires, a biosimilar follow-on medicine can be manufactured.1,4 Biosimilars are more affordable than their reference biological medications, improving patient access and decreasing healthcare costs.1
In Europe, use of biological medicines increased by as much as 100% following the introduction of biosimilars, leading to significant savings.3
Sandoz, a pioneer in the development of biosimilars, launched the world’s first biosimilar in 2006.5 Our biosimilars are now available in 100 countries and have 730+ million days of patient experience.5
Biosimilars follow a different, more detailed approval process compared to generic medicines. To be approved in South Africa, a biosimilar must match the reference medicine in terms of safety, quality and efficacy, so doctors and patients can expect the same clinical outcome.6
Recent statistics confirm that, during 2020, $8 billion were saved in the United States of America (US) through the use of biosimilars. Their use is projected to save the US healthcare industry $133 billion by 2025.7
Sandoz is well placed to provide high-quality, affordable biosimilars to the South African market.
Dutta B, Huys I, Vulto AG, et al. Identifying Key Benefits in European Off-patent Biologics and Biosimilar Markets: It Is Not Only About Price! BioDrugs. 2020;34(2):159-170. doi:10.1007/s40259-019-00395-w
Biosimilars in the EU [Online]. European Medicines Agency, European Commission. Cited 24 Nov 2021. Available from: https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-informati…
Delivering on the Potential of Biosimilar Medicines [Online]. IMS Institute for Healthcare Informatics. Cited 24 Nov 2021. Available from: https://www.medicinesforeurope.com/wp-content/uploads/2016/03/IMS-Insti…
Gupta P. Biosimilars; Similar But Not the Same. JK Science. 2017;19(2):67-69.
Sandoz. Unlock Their Potential. Biosimilars, the key to driving access and sustainability. Infographic. [Online]. Cited 24 Nov 2021. Available from: https://www.sandoz.com/unlock-their-potential-15-years-biosimilars
Biosimilar Medicines Quality, Non-clinical and Clinical Requirements [Online]. SAHPRA. Cited 24 Nov 2021. Available from: https://www.sahpra.org.za/wp-content/uploads/2020/04/SAHPRA-Biosimilar-…
The U.S. Generic & Biosimilar Medicines Savings Report [Online]. AAM. Cited 24 Nov 2021. Available from: https://accessiblemeds.org/sites/default/files/2021-10/AAM-2021-US-Gene…